U.S. Physical Therapy stock reports 8.5 percent revenue growth
Published on 10/05/2026 at 11:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
U.S. Physical Therapy stock (ISIN US90337L1089) was last at USD 83.72 on the NYSE on October 2, 2026 at 4:00 p.m. ET, up 1.36 percent from the prior session. The company delivered Q2 2026 revenue of USD 214.1 million, giving investors a clearer measure of operating growth than the share price alone.
Revenue growth meets margin pressure
In its August 6, 2026 filing, StockTitan reports that Q2 revenue increased 8.5 percent from USD 197.3 million in Q2 2025 to USD 214.1 million in Q2 2026. Physical therapy revenue rose 8.4 percent and industrial injury prevention revenue increased 9.1 percent during the same period.
The earnings mix was less favorable. Net income attributable to shareholders declined from USD 12.4 million in Q2 2025 to USD 9.9 million in Q2 2026, while diluted GAAP EPS fell from USD 0.58 to USD 0.25. Adjusted EBITDA moved from USD 26.9 million to USD 27.0 million, showing that volume gains were largely offset by higher healthcare costs and upfront hospital-affiliation spending.
Hospital affiliations shape the next phase
Business Wire reported on September 21, 2026 that Myra Davis joined the board effective October 1, 2026. The release said U.S. Physical Therapy owns or manages 799 outpatient clinics across 45 states, while the company continues integrating hospital relationships and expanding its physical therapy platform.
Management reaffirmed full-year 2026 adjusted EBITDA guidance of USD 102.0 million to USD 106.0 million in the Q2 update. The company also reported 1,661,694 patient visits in Q2 and a record physical therapy net rate of USD 107.59 per visit, up USD 2.26 from the prior year.
Analysts see measured upside
MarketBeat lists a Moderate Buy consensus based on 7 analyst ratings. The average target is USD 98.25, with a high of USD 102.00 and a low of USD 95.00; the average target lies 17.3 percent above the USD 83.72 reference price.
JPMorgan raised its target from USD 90.00 to USD 95.00 and maintained an Overweight rating on September 11, 2026, according to MarketBeat. The gap between stronger revenue and weaker GAAP earnings leaves hospital implementation costs and margin recovery as the central operating variables.
USPH stays below its yearly high
USPH was last at USD 83.72 on the NYSE on October 2, 2026 at 4:00 p.m. ET. Its 52-week range was USD 58.19 to USD 93.50, and its market capitalization was USD 1.3 billion with volume of 235,743 shares.
U.S. Physical Therapy stock facts
- Company: U.S. Physical Therapy, Inc.
- ISIN: US90337L1089
- Ticker: USPH
- Trading venue: NYSE
- Price as of October 2, 2026, 4:00 p.m. ET: USD 83.72
- Market capitalization: USD 1.3 billion (as of October 2, 2026)
- 52-week range: USD 58.19-93.50 (as of October 2, 2026)
- Sector / Industry: Healthcare / Medical Care Facilities
